Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus TOLECTIN 600.
EC-NAPROSYN vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
500-1000 mg orally twice daily; maximum 1500 mg/day.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category C
Category C
NSAID
NSAID